Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7746-7755

  Li, Qiang ^a   Ujiie, Hideyuki ^a   Shibaki, Akihiko ^a   Wang, Gang ^a   Moriuchi, Reine ^a   Qiao, Hong Jiang ^a   Morioka, Hiroshi ^b   Shinkuma, Satoru ^a   Natsuga, Ken ^a   Long, Heather A ^a   Nishie, Wataru ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; COLLAGEN TYPE 17; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING SITE; BLISTER; BULLOUS PEMPHIGOID; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN DEPOSITION; IN VITRO STUDY; IN VIVO STUDY; MAST CELL DEGRANULATION; MUTATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BLISTER; CELL DEGRANULATION; CELL LINE; COLLAGEN TYPE XVIII; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MAST CELLS; MICE; MICE, TRANSGENIC; NEUTROPHIL INFILTRATION; NEUTROPHILS; PEMPHIGOID, BULLOUS; PROTEIN STRUCTURE, TERTIARY;

EID: 78650633489     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000667     Document Type: Article

References (53)

1. Gudi, V. S., M. I. White, N. Cruickshank, R. Herriot, S. L. Edwards, F. Nimmo, and A. D. Ormerod. 2005. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br. J. Dermatol. 153:424-427.
2. Langan, S. M., L. Smeeth, R. Hubbard, K. M. Fleming, C. J. Smith, and J. West. 2008. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 337: a180.
3. Jordon, R. E., E. H. Beutner, E. Witebsky, G. Blumental, W. L. Hale, and W. F. Lever. 1967. Basement zone antibodies in bullous pemphigoid. J. Am. Med. Assoc. 200:751-756.
4. Nishie, W., D. Sawamura, K. Natsuga, S. Shinkuma, M. Goto, A. Shibaki, H. Ujiie, E. Olasz, K. B. Yancey, and H. Shimizu. 2009. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J. Immunol. 183:4088-4093.
5. Bernard, P., P. Aucouturier, F. Denis, and J. M. Bonnetblanc. 1990. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin. Immunol. Immunopathol. 54:484-494.
6. Hofmann, S., S. Thoma-Uszynski, T. Hunziker, P. Bernard, C. Koebnick, A. Stauber, G. Schuler, L. Borradori, and M. Hertl. 2002. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2-and COOH-terminal regions of the BP180 ectodomain. J. Invest. Dermatol. 119:1065-1073.
7. Laffitte, E., M. Skaria, F. Jaunin, K. Tamm, J. H. Saurat, B. Favre, and L. Borradori. 2001. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br. J. Dermatol. 144:760-768.
8. Stanley, J. R., P. Hawley-Nelson, S. H. Yuspa, E. M. Shevach, and S. I. Katz. 1981. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 24:897-903.
9. Sitaru, C., E. Schmidt, S. Petermann, L. S. Munteanu, E. B. Bröcker, and D. Zillikens. 2002. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J. Invest. Dermatol. 118:664-671.
10. Giudice, G. J., D. J. Emery, B. D. Zelickson, G. J. Anhalt, Z. Liu, and L. A. Diaz. 1993. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 151:5742-5750.
11. Anhalt, G. J., C. F. Bahn, R. S. Labib, J. J. Voorhees, A. Sugar, and L. A. Diaz. 1981. Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J. Clin. Invest. 68:1097-1101.
12. Liu, Z., L. A. Diaz, J. L. Troy, A. F. Taylor, D. J. Emery, J. A. Fairley, and G. J. Giudice. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92:2480-2488.
13. Oikarinen, A. I., J. J. Zone, A. R. Ahmed, U. Kiistala, and J. Uitto. 1983. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases: comparison between dermatitis herpetiformis and bullous pemphigoid. J. Invest. Dermatol. 81:261-266.
14. Ståhle-Bäckdahl, M., M. Inoue, G. J. Guidice, and W. C. Parks. 1994. 92-kD Gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J. Clin. Invest. 93:2022-2030.
15. Liu, Z., W. Sui, M. Zhao, Z. Li, N. Li, R. Thresher, G. J. Giudice, J. A. Fairley, C. Sitaru, D. Zillikens, et al. 2008. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J. Autoimmun. 31:331-338.
16. Chen, R., G. Ning, M. L. Zhao, M. G. Fleming, L. A. Diaz, Z. Werb, and Z. Liu. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108:1151-1158.
17. Nishie, W., D. Sawamura, M. Goto, K. Ito, A. Shibaki, J. R. McMillan, K. Sakai, H. Nakamura, E. Olasz, K. B. Yancey, et al. 2007. Humanization of autoantigen. Nat. Med. 13:378-383.
18. Nelson, K. C., M. Zhao, P. R. Schroeder, N. Li, R. A. Wetsel, L. A. Diaz, and Z. Liu. 2006. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J. Clin. Invest. 116:2892-2900.
19. Jordon, R. E., S. Kawana, and K. A. Fritz. 1985. Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J. Invest. Dermatol. 85 (Suppl. 1) 72s-78s.
20. Provost, T. T., and T. B. Tomasi, Jr. 1973. Evidence for complement activation via the alternate pathway in skin diseases. I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid. J. Clin. Invest. 52:1779-1787.
21. Jordon, R. E., N. K. Day, W. M. Sams, Jr., and R. A. Good. 1973. The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids. J. Clin. Invest. 52:1207-1214.
22. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332:738-740.
23. Burton, D. R. 1985. Immunoglobulin G: functional sites. Mol. Immunol. 22:161-206.
24. Oganesyan, V., C. Gao, L. Shirinian, H. Wu, and W. F. Dall'Acqua. 2008. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 64:700-704.
25. Idusogie, E. E., L. G. Presta, H. Gazzano-Santoro, K. Totpal, P. Y. Wong, M. Ultsch, Y. G. Meng, and M. G. Mulkerrin. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164:4178-4184.
26. Tao, M. H., R. I. Smith, and S. L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178:661-667.
27. Xu, Y., R. Oomen, and M. H. Klein. 1994. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 269:3469-3474.
28. Döpp, R., E. Schmidt, I. Chimanovitch, M. Leverkus, E. B. Bröcker, and D. Zillikens. 2000. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J. Am. Acad. Dermatol. 42:577-583.
29. Iwata, Y., K. Komura, M. Kodera, T. Usuda, Y. Yokoyama, T. Hara, E. Muroi, F. Ogawa, M. Takenaka, and S. Sato. 2008. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch. Dermatol. 144:41-48.
30. Amagai, M., A. Komai, T. Hashimoto, Y. Shirakata, K. Hashimoto, T. Yamada, Y. Kitajima, K. Ohya, H. Iwanami, and T. Nishikawa. 1999. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br. J. Dermatol. 140:351-357.
31. Amagai, M., K. Tsunoda, H. Suzuki, K. Nishifuji, S. Koyasu, and T. Nishikawa. 2000. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest. 105:625-631.
32. Ujiie, H., A. Shibaki, W. Nishie, D. Sawamura, G. Wang, Y. Tateishi, Q. Li, R. Moriuchi, H. Qiao, H. Nakamura, et al. 2010. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J. Immunol. 184:2166-2174.
33. Kobayashi, M., M. Amagai, K. Kuroda-Kinoshita, T. Hashimoto, Y. Shirakata, K. Hashimoto, and T. Nishikawa. 2002. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J. Dermatol. Sci. 30:224-232.
34. Zillikens, D., P. A. Rose, S. D. Balding, Z. Liu, M. Olague-Marchan, L. A. Diaz, and G. J. Giudice. 1997. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 109:573-579.
35. Galvin, J. E., M. E. Hemric, K. Ward, and M. W. Cunningham. 2000. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J. Clin. Invest. 106:217-224.
36. Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, B. R. Murphy, R. Rappuoli, and A. Lanzavecchia. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
37. Liang, M., S. Dübel, D. Li, I. Queitsch, W. Li, and E. K. Bautz. 2001. Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J. Immunol. Methods 247:119-130.
38. Poul, M. A., M. Cerutti, H. Chaabihi, M. Ticchioni, F. X. Deramoudt, A. Bernard, G. Devauchelle, M. Kaczorek, and M. P. Lefranc. 1995. Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells. Eur. J. Immunol. 25:2005-2009.
39. Liang, C. Y., H. Z. Wang, T. X. Li, Z. H. Hu, and X. W. Chen. 2004. High efficiency gene transfer into mammalian kidney cells using baculovirus vectors. Arch. Virol. 149:51-60.
40. Schumaker, V. N., M. A. Calcott, H. L. Spiegelberg, and H. J. Müller-Eberhard. 1976. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 15:5175-5181.
41. Mihai, S., M. T. Chiriac, J. E. Herrero-González, M. Goodall, R. Jefferis, C. O. Savage, D. Zillikens, and C. Sitaru. 2007. IgG4 autoantibodies induce dermal-epidermal separation. J. Cell. Mol. Med. 11:1117-1128.
42. Liu, Z., G. J. Giudice, S. J. Swartz, J. A. Fairley, G. O. Till, J. L. Troy, and L. A. Diaz. 1995. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95:1539-1544.
43. Ricklin, D., and J. D. Lambris. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25:1265-1275.
44. Melamed, J., M. A. Arnaout, and H. R. Colten. 1982. Complement (C3b) interaction with the human granulocyte receptor: correlation of binding of fluidphase radiolabeled ligand with histaminase release. J. Immunol. 128:2313-2318.
45. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6:132-142.
46. Müller-Eberhard, H. J. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57:321-347.
47. Galli, S. J., J. R. Gordon, and B. K. Wershil. 1991. Cytokine production by mast cells and basophils. Curr. Opin. Immunol. 3:865-872.
48. Galli, S. J. 1993. New concepts about the mast cell. N. Engl. J. Med. 328:257-265.
49. Liu, Z., G. J. Giudice, X. Zhou, S. J. Swartz, J. L. Troy, J. A. Fairley, G. O. Till, and L. A. Diaz. 1997. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 100:1256-1263.
50. Liu, Z., J. M. Shipley, T. H. Vu, X. Zhou, L. A. Diaz, Z. Werb, and R. M. Senior. 1998. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 188:475-482.
51. Wang, G., H. Ujiie, A. Shibaki, W. Nishie, Y. Tateishi, K. Kikuchi, Q. Li, J. R. McMillan, H. Morioka, D. Sawamura, et al. 2010. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am. J. Pathol. 176:914-925.
52. Holliger, P., and P. J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23:1126-1136.
53. Kane, S. V., and L. A. Acquah. 2009. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J. Gastroenterol. 104:228-233.